WEHI launches Ternax focused on neuroblastoma and prostrate cancer – Children’s Cancer Institute
Children’s Cancer Institute shared on LinkedIn:
“We send our heartfelt congratulations to WEHI (Walter and Eliza Hall Institute of Medical Research) on the official launch of Ternarx – a WEHI spinout company that’s set to revolutionise homegrown cancer treatments and position Australia as a globally competitive player in next-generation medicines.
The biotech company is the first of its kind in Australia dedicated to developing targeted protein degrader (TPD) medicines and technology, a powerful new tool for destroying disease-causing proteins that cannot be targeted by conventional drugs.
Ternarx is backed by $15 million in funding from the Medical Research Future Fund’s (MRFF) Frontier Health and Medical Research initiative and is a brilliant partnership between WEHI, Monash University and Children’s Cancer Institute, that could help unlock the ‘undruggable’.
The Hon Mark Butler MP attended the launch event and Children’s Cancer Institute were proudly represented by Murray Norris, Jayne Murray and Peter Wejbora.
Ternarx will initially focus on neuroblastoma and prostate cancer.
Neuroblastoma is a childhood cancer that claims more lives of children under five than any other cancer, while prostate cancer is the most commonly diagnosed cancer among Australian men.
Ternarx CEO, Joanne Boag, said ‘Neuroblastoma and some forms of prostate cancer urgently need new treatments, as evidenced by poor patient outcomes.’
‘TPD technology opens up new avenues to attack these and other hard to treat cancers by delivering precision treatment options.’
We’re incredibly proud of this partnership and look forward to seeing the potential of TPD technology unfold in the future.”
